BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10366463)

  • 21. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
    Schwandner O; Schlamp A; Broll R; Bruch HP
    Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
    Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
    J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
    Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Reich R
    Mol Cell Endocrinol; 2002 Feb; 187(1-2):39-45. PubMed ID: 11988310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
    Sier CF; Zuidwijk K; Zijlmans HJ; Hanemaaijer R; Mulder-Stapel AA; Prins FA; Dreef EJ; Kenter GG; Fleuren GJ; Gorter A
    Int J Cancer; 2006 Jun; 118(12):2991-8. PubMed ID: 16425263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and localization of matrix metalloproteinases (MT1-MMP, MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) during synepitheliochorial placentation of goats (Capra hircus).
    Uekita T; Yamanouchi K; Sato H; Tojo H; Seiki M; Tachi C
    Placenta; 2004 Nov; 25(10):810-9. PubMed ID: 15451196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
    Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
    Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
    Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
    Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
    Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
    BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors].
    Wang Y; Ueda Y; Shimasaki M; Liu N; Wang EH
    Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):18-23. PubMed ID: 16608644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of matrix metalloproteinase 2 (MMP-2), membrane-type 1 MMP and tissue inhibitor of metalloproteinase 2 and activation of proMMP-2 in pancreatic duct adenocarcinomas in hamsters treated with N-nitrosobis(2-oxopropyl)amine.
    Iki K; Tsutsumi M; Kido A; Sakitani H; Takahama M; Yoshimoto M; Motoyama M; Tatsumi K; Tsunoda T; Konishi Y
    Carcinogenesis; 1999 Jul; 20(7):1323-9. PubMed ID: 10383907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 in human head and neck squamous cell carcinoma.
    Imanishi Y; Fujii M; Tokumaru Y; Tomita T; Kanke M; Kanzaki J; Kameyama K; Otani Y; Sato H
    Hum Pathol; 2000 Aug; 31(8):895-904. PubMed ID: 10987249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
    Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
    J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor.
    Ota K; Stetler-Stevenson WG; Yang Q; Kumar A; Wada J; Kashihara N; Wallner EI; Kanwar YS
    Kidney Int; 1998 Jul; 54(1):131-42. PubMed ID: 9648071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
    Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
    J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome.
    Ara T; Fukuzawa M; Kusafuka T; Komoto Y; Oue T; Inoue M; Okada A
    J Pediatr Surg; 1998 Aug; 33(8):1272-8. PubMed ID: 9722003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency.
    Furukawa A; Tsuji M; Nishitani M; Kanda K; Inoue Y; Kanayama H; Kagawa S
    Urology; 1998 May; 51(5):849-53. PubMed ID: 9610608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors.
    Takahashi E; Tateyama H; Akatsu H; Fukai I; Yamakawa Y; Fujii Y; Eimoto T
    Hum Pathol; 2003 Dec; 34(12):1253-8. PubMed ID: 14691910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
    Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
    Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma.
    Sakamoto A; Oda Y; Iwamoto Y; Tsuneyoshi M
    J Cancer Res Clin Oncol; 1999 Oct; 125(10):541-8. PubMed ID: 10473866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.